EyePoint appoints Michael C. Pine as Chief Corporate Development and Strategy Officer

EyePoint, Inc.

Appointed Michael C. Pine as Chief Corporate Development and Strategy Officer, effective January 10, 2022.
Annual base salary of $420,000; sign-on bonus of $108,000 payable in two equal tranches.
Granted options to purchase 100,000 shares at $12.62/share, vesting 25% on first anniversary then monthly through fourth year.
Mr. Pine brings over 20 years of pharma experience, most recently SVP at Medexus Pharmaceuticals.
Inducement award under Nasdaq Listing Rule 5635(c)(4); subject to forfeiture provisions.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael C. Pine

Chief Corporate Development and Strategy Officer

EYPT · EyePoint, Inc.

Effective: 2022-01-10
Filed: January 10, 2022, 6:59 PM ET

On January 10, 2022 (the “ Start Date ”), EyePoint Pharmaceuticals, Inc. (the “ Company ”) announced that the Board of Directors (the “ Board ”) of the Company appointed Michael C. Pine, age 46, as the Company’s Chief Corporate Development and Strategy Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Michael C. Pine was appointed as Chief Corporate Development and Strategy Officer at EyePoint, Inc..

Action: appointed
Role: Chief Corporate Development and Strategy Officer

Exact text from the filing

On January 10, 2022 (the “ Start Date ”), EyePoint Pharmaceuticals, Inc. (the “ Company ”) announced that the Board of Directors (the “ Board ”) of the Company appointed Michael C. Pine, age 46, as the Company’s Chief Corporate Development and Strategy Officer.

View on SEC.gov

EyePoint, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-22-000853

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.